Esther Melamed, Michael Levy, Patrick J Waters, Douglas Kazutoshi Sato, Jeffrey L Bennett, Gareth R John, Douglas C Hooper, Albert Saiz, Amit Bar-Or, Ho Jin Kim, Lakha Pandit, Maria Isabel Leite, Nasrin Asgari, Najib Kissani, Rogier Hintzen, Romain Marignier, Sven Jarius, John Marcelletti, Terry J Smith, Michael R Yeaman, May H Han, Orhan Aktas, Metha Apiwattanakul, Brenda Banwell, Denis Bichuetti, Simon Broadley, Philippe Cabre, Tanuja Chitnis, Jerome De Seze, Kazuo Fujihara, Benjamin Greenberg, Kerstin Hellwig, Raffaele Iorio, Sven Jarius, Eric Klawiter, Ingo Kleiter, Marco Lana-Peixoto, Nakashima, Kevin O'Connor, Jacqueline Palace, Friedman Paul, Naraporn Prayoonwiwat, Klemens Ruprecht, Olaf Stuve, Thomas Tedder, Silvia Tenembaum, Juan P Garrahan, Buenos Aires, Katja van Herle, Danielle van Pelt, Pablo Villoslada, Emmanuelle Waubant, Brian Weinshenker, Dean Wingerchuk, Jens Würfel, Scott Zamvil
Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO...
August 2015: Neurology® Neuroimmunology & Neuroinflammation